



BRAINWARE UNIVERSITY

Term End Examination 2023 Programme – B.Pharm-2019/B.Pharm-2020

Course Name - Biopharmaceutics and Pharmacokinetics/Biopharmaceutics and Pharmacokinetics - Theory

Course Code - BP604T (Semester VI)

Full Marks: 75

[The figure in the margin indicates full marks. Candidates are required to give their answers in their Time: 3:0 Hours own words as far as practicable.]

Group-A

(Multiple Choice Type Question)

1 x 20=20

- 1. Choose the correct alternative from the following:
- (i) Choose the option which is not a parameter to be considered for determining bioavailability.
 - a) Cmax

b) Tmax

c) AUC

- d) Dose
- (ii) Select the model in which peripheral compartments are connected to a central
 - a) Compartment model

b) Caternary model

c) Physiologic model

- d) Mammillary model
- (iii) Distinguish the characteristic of encapsulation or coating dissolution-controlled release
 - a) Microencapsulation using slowly dissolving materials
- b) Prolonged their residence in the GIT and release
- c) Release only at a specific drug
- d) Employ waxes to control the rate of dissolution
- (iv) The onset of drug action represents the rate of
 - a) Drug absorption

b) Drug dissociation

c) pH

- d) GI motility
- (v) Distinguish the drug which cannot enter the cell membrane.
 - a) lonized drug

b) Unionized drug

c) Hydrolyzed drug

- d) Unhydrated drug
- (vi) Select the ideal solubility rate of an orally administered drug in the pH range of 2 to 8.
 - a) 3-4 mg/ml

b) 4-6 mg/ml

c) 7-8 mg/ml

- d) 1-2 mg/ml
- (vii) Select the mechanism of drug excretion for skin excretion.
 - a) Active secretion

b) Glomerular secretion



c) Passive diffusion (viii) In the sequence of events in the dru dosage, select the step which comes	d) Passive reabsorption ag absorption from orally administered solid s at first.
a) Disintegration c) Dissolution (ix) Identify the option which is not a th	b) Deaggregationd) Absorption
a) Diffusion layer model c) Interfacial barrier model (x) From the following, name the option substance.	 b) Fick\'s law of diffusion d) Penetration or surface renewal theory n which is a physicochemical property of drug
 a) Drug solubility c) Age of patient (xi) If distribution of drug is slower than select the possible outcome. 	b) Disintegration time d) Dissolution time process of biotransformation and elimination,
 a) It will cause high blood level of druc) Cause failure to attain diffusion equivalent (xii) In pharmacokinetics, the term 'rate' measurements over time. 	
a) Drug dose c) Concentration of drug in plasma (xiii) Name the kind of molecules that can	b) Drug eliminationd) Drug metabolismnnot be absorbed pore transport.
 a) Low Molecular weight molecules c) Molecules up to 400 Dalton (xiv) The loading dose of a drug is usually 	b) Water-soluble drugs d) Molecules greater than 400 Dalton depends on -
 a) Total clearance of the drug c) Fraction of drug excreted unchange urine 	b) Plasma protein binding percentage d) Apparent volume of distribution and desired steady state drug concentration in plasma
(xv) Choose the correct option which exp	presses Michaelis-Menten equation.
a) -dC/dt = Vmax C/Km+C c) -dC/dt = Vmax C/Km (xvi) Choose the case, in which t1/2 is inc	 b) dC/dt = Vmax C/Km+C d) -dC/dt = Km+C/Vmax C dependent of drug concentration.
	 b) Zero order d) Nor-linear is 0.7 ml/mm, the biliary drug concentration is ration is 0.8g/ml. Calculate the bile clearance.
a) 1.50 ml/mm c) 2.75 ml/mm (xviii) Choose the mathematical equation	b) 1.75 ml/mm d) 3 ml/mm for bioavailable fraction.
	b) 1/Administered dose ose d) Administered dose/ Bioavailable dose of 900 ml and plasma drug concentration to be 1.2 g that should be given to the patient.
	b) 1080 g d) 1g/ml the term used for, \"the time period for which the ns above minimum effective concentration\".
a) Onset of timec) Duration of drug of action	b) Onset of action d) Therapeutic range

Group-B

агоир-в		
(Short Answer Type Questions)	5 x 7=35	
2. Discuss in detail about protein binding and its significance.	(5)	
3. Explain various non-renal routes of excretion.	(5)	
4. Define bioavailability. Explain the objectives of bioavailability studies.	(5)	
5. With a neat diagram, describe the drug absorption through blood brain barrier.	(5)	
6. Describe in detail about various physico-chemical factors affecting drug absorption.	(5)	
7. Explain the apparent zero order kinetics.	(5)	
OR		
Explain the parameters used in adjustment of dosage regimen.	(5)	
8. Explain the criteria for obtaining valid urinary excretion data.	(5)	
OR		
Correlate loading dose and maintenance dose.	(5)	
Group-C		
(Long Answer Type Questions)	10 x 2=20	
9. Explain the process of renal excretion of drugs.	(10)	
10. Explain the process, how bioavailability can be demonstrated in vitro.	(10)	
OR	107 - 110	
Explain the different methods for enhancing bio-availability of drugs.	(10)	

pharm of molesy